News

Deal Announcements

Acetylon Pharma Makes Headway In Series B

Wednesday, February 23, 2011 5:01:00 AM PDT | VentureDeal Staff
Boston, Massachusetts  --  Cancer treatment developer Acetylon Pharmaceuticals has garnered $12.4 million in its second round of venture capital investment.

Acetylon is commercializing next-generation, selective, small molecule inhibitors for the treatment of various cancers.

Investors in the financing were not disclosed. The company is seeking an additional $17.6 million in second round financing.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1